The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
Arranon [package insert].Research Triangle Park, NC: GlaxoSmithKline; 2005.
2.
DeAngeloD.J., YuD., DodgeR.K.. A phase II study of 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: CALGB study 19801 [abstract 743]. Blood.2003; 100(Suppl 1): 198a.
3.
GoekbugetN., ArnoldR., JohannesA.. Compound GW506U78 has high single-drug activity and good feasibility in heavily pretreated relapsed T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) and offers the option for cure with stem cell transplantation (SCT) [abstract 150]. Blood.2005; 106.
4.
ThompsonM.A., ProB., SarrisA.. Results of a phase II study of 506U78 (nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma [abstract 2681]. Blood.2005; 106.
5.
BergS.L., BlaneyS.M., DevidasM.. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol.2005; 23: 3376–3382.
6.
KurtzbergJ., ErnstT.J., KeatingM.J.. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol.2005; 23: 3396–3403.
RatainM.J., EisenT., StadlerW.M.. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract 4544]. Proc Am Soc Clin Oncol.2005; 24.
9.
EscudierB., SzczylikC., EisenT.. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol [abstract 4510]. 2005; 24. (abstr 4510).
10.
StrumbergD., RichlyH., HilgerR.A.. Phase I clinical and pharmacokinetics study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol.2005; 23: 965–972.
11.
AwadaA., HendliszA., GilT.. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors. Br J Cancer.2005; 92: 1855–1861.
12.
ClarkJ.W., EderJ.P., RyanD., LathiaC., LenzH.J.Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res.2005; 11: 5472–5480.
